newsfilter
← Latest News
PR Newswire·

Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indicationsActive discussions underway with potential partners to advance late-stage virology programsReduction in workforce executed to align